ReviewBreast cancer research : BCR2001
Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?
Review in Breast cancer research : BCR, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 43 citations in OpenAlex.
- ABO blood group system correlates with preoperative serum PSA level in patients with prostate cancer.Scientific reports · 2025Article
- The Potentiality of Prostate-Specific Antigen as a Prognostic Biomarker in Breast Cancer.Cureus · 2023Article
- Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.Breast cancer research : BCR · 2021Article
- Could Kallikrein-Related Serine Peptidase 3 Be an Early Biomarker of Environmental Exposure in Young Women?International journal of environmental research and public health · 2021Article
- Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.Experimental and therapeutic medicine · 2021Article
- Article
- Nanostructured surfaces and detection instrumentation for photonic crystal enhanced fluorescence.Sensors (Basel, Switzerland) · 2013Review
- Isolation and characterization of circulating tumor cells in prostate cancer.Frontiers in oncology · 2012Article
- Application of photonic crystal enhanced fluorescence to cancer biomarker microarrays.Analytical chemistry · 2011Article
- Arraying prostate specific antigen PSA and Fab anti-PSA using light-assisted molecular immobilization technology.Protein science : a publication of the Protein Society · 2010Article
- Ductal lavage, nipple aspiration, and ductoscopy for breast cancer diagnosis.Current oncology reports · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its identification, much information has been obtained about prostate-specific antigen (PSA, or human glandular kallikrein 3 [hK3]), a kallikrein-like serine protease that is the most valuable tumour marker for the screening, diagnosis and management of human prostate carcinoma. Recently, it has become widely accepted that PSA is also present in many nonprostatic sources, casting doubts about the specificity of its tissue expression. Here we summarize the findings on the biomolecular expression of PSA in breast secretions, cells and tissues of healthy and diseased females. Although several studies have strongly suggested that the molecular forms of PSA seem to represent a potential tool for the risk assessment of breast cancer, recent reports have yielded conflicting results. Although several studies have suggested new biological function(s) for PSA in breast physiopathology, more studies are needed to enlist PSA unequivocally as an additional weapon in the anticancer armoury in breast cancer diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.